Trial Outcomes & Findings for High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies (NCT NCT03146962)

Last Updated: 2024-05-02

Results Overview

Number of patients with partial or complete pathological response in surgically resected tumor tissue: Pathological response rate is the number of patients with partial or complete pathological response in surgically resected tumor tissue. Pathologic response was assessed by tumor regression grade. This is a pathologic assessment of the amount of residual cancer cells in the specimen and the degree of fibrosis in the sample specimen. A completer response is 0% residual cancer cells. A partial response is 10-50% residual cancer cells, and no response is \>50% residual cancer cells within the tumor specimen.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

61 participants

Primary outcome timeframe

cohort A - 8 weeks

Results posted on

2024-05-02

Participant Flow

Participant milestones

Participant milestones
Measure	Cohort A: Vitamin C + Surgery Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort B: Vitamin C Only Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for up to 6 months. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Overall Study STARTED	7	21	3	3	4	3	3	7	3	7
Overall Study COMPLETED	5	15	3	3	3	3	3	6	3	6
Overall Study NOT COMPLETED	2	6	0	0	1	0	0	1	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort A: Vitamin C + Surgery Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort B: Vitamin C Only Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for up to 6 months. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Overall Study Lost to Follow-up	1	1	0	0	0
Overall Study Adverse Event	0	3	0	1	0
Overall Study Withdrawal by Subject	0	0	1	0	0
Overall Study Death	0	1	0	0	0
Overall Study COVID Precautions	1	0	0	0	0
Overall Study Physician Decision	0	0	0	0	1
Overall Study Started New Treatment	0	1	0	0	0

Baseline Characteristics

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort A: Vitamin C + Surgery n=7 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort B: Vitamin C Only n=21 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for up to 6 months. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 n=3 Participants Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 n=3 Participants Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 n=4 Participants Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 n=3 Participants Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 n=3 Participants A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 n=7 Participants A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 n=3 Participants A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 n=7 Participants A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Total n=61 Participants Total of all reporting groups
Age, Continuous	49.02 years n=5 Participants	60.72 years n=7 Participants	54.51 years n=5 Participants	55.5 years n=4 Participants	75.66 years n=21 Participants	48.46 years n=10 Participants	77.73 years n=115 Participants	58.05 years n=24 Participants	69.92 years n=42 Participants	58.94 years n=42 Participants	61.66 years n=42 Participants
Sex: Female, Male Female	5 Participants n=5 Participants	14 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	0 Participants n=10 Participants	2 Participants n=115 Participants	3 Participants n=24 Participants	1 Participants n=42 Participants	2 Participants n=42 Participants	31 Participants n=42 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	7 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	3 Participants n=10 Participants	1 Participants n=115 Participants	4 Participants n=24 Participants	2 Participants n=42 Participants	5 Participants n=42 Participants	30 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	4 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	10 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=5 Participants	16 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	3 Participants n=115 Participants	7 Participants n=24 Participants	2 Participants n=42 Participants	7 Participants n=42 Participants	50 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	4 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	2 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	6 Participants n=42 Participants
Race (NIH/OMB) White	5 Participants n=5 Participants	14 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	3 Participants n=10 Participants	3 Participants n=115 Participants	5 Participants n=24 Participants	2 Participants n=42 Participants	5 Participants n=42 Participants	44 Participants n=42 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	6 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	7 Participants n=42 Participants
Region of Enrollment United States	7 participants n=5 Participants	21 participants n=7 Participants	3 participants n=5 Participants	3 participants n=4 Participants	4 participants n=21 Participants	3 participants n=10 Participants	3 participants n=115 Participants	7 participants n=24 Participants	3 participants n=42 Participants	7 participants n=42 Participants	61 participants n=42 Participants

PRIMARY outcome

Timeframe: cohort A - 8 weeks

Population: Only the 6 patients who had surgery from Cohort A, and thus had evaluable tissue, were analyzed for this measure. Participants in Cohort B and C did not undergo surgery, and were thus not evaluable.

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=6 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Pathologic Response Based on Tumor Regression Grading in Cohort A Patients	1 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Cohort B - 3 months

Population: DCR was not collected for Cohort A or Cohort C. 5 participants from Cohort B were missing scans and were therefor unevaluable.

Percentage of patients with complete response, partial response, or stable disease as a result of their therapy at 3 months

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=16 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
3-month Disease Control Rate (DCR) Will be Evaluated Using RECIST v 1.1 in Cohort B Patients.	1 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Cohort C - 16 weeks

Population: Only patients that received a dose of Vitamin C in Cohort C were considered evaluable. In Cohort C, 30 out of 32 participants who received vitamin C were evaluated across dose levels. Cohort A and B were not dose escalations, and therefore were not evaluated for maximum tolerated dose.

Maximal tolerated dose will be evaluated by assessment of dose limiting toxicities for multiple dose levels. Dose limiting toxicity will be defined as any grade 3-4 adverse event possibly, probably, or definitely attributed to vitamin C therapy in the 21 days of protocol therapy. In any group of 3 patients, if one patient experiences dose limiting toxicity, the group will be expanded by 3 additional patients (eg. 6 for that group). If, at any dose level, 2 or more patients experience a dose limiting toxicity, the maximal tolerated dose will be reached, and further dose escalation will not be pursued. The dose level may then be expanded up to 10 additional patients to confirm the safety and toxicity at that dose level.

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=30 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Maximal Tolerated Dose of High Dose Vitamin C in Combination With Y90 Radioembolization Vitamin C Weekly Infusion Dose	1.25 g/kg	—	—	—	—	—	—	—	—	—
Maximal Tolerated Dose of High Dose Vitamin C in Combination With Y90 Radioembolization Vitamin C Infusion Dose the Day of Y-90 Radioembolization	1.25 g/kg	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: cohort B - up to 6 months

Population: Participants from Cohort A and Cohort C were not assessed for PFS. 5 participants were missing scans from Cohort B and were therefore unevaluable.

PFS is defined as the time from registration to cancer progression or death due to any cause for up to 6 months. Cancer progression is defined using the Response Evaluation Criteria in Solid Tumors v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in non-target lesions, or the appearance of new lesions.

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=16 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Progression-free Survival (PFS)	36 days Interval 14.0 to 151.0	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: cohort B - up to 6 months cohort C - 16 weeks

Population: For Cohort B, only 16/21 participants had complete sets of imaging scans and were therefore evaluable. Participants in Cohort A were not evaluated for ORR. In Cohort C Dose Level 3, one patient withdrew from the study early and therefore was unevaluable. For cohort C dose level 6, three patients did not have complete imaging to be evaluable. For Cohort C Dose Level one participant withdrew prior to treatment and one participant was missing scans, therefore they were not unevaluable.

Number of patients with a partial response or complete response based on RECIST 1.1 Criteria.

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=16 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 n=3 Participants Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 n=3 Participants Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 n=3 Participants Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 n=3 Participants Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 n=3 Participants A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 n=4 Participants A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 n=3 Participants A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 n=5 Participants A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Objective Response Rate (ORR)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Up to 24 hours post-infusion

Population: Pharmacokinetics data was not assessed for Cohort A or Cohort C. PK samples for 5 participants from Cohort B were not obtained and therefore only 16/21 participants were evaluable.

The serum concentration of vitamin C was serially measured following vitamin C infusion at 1.25 g/kg at various timepoints up to 24 hours post infusion to determine the Tmax and t(1/2) in hours

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=16 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Time to Maximum Concentration and Half-life of Vitamin C (t1/2) in Hours in Cohort B T(max)	2.28 hours Standard Deviation 0.38	—	—	—	—	—	—	—	—	—
Time to Maximum Concentration and Half-life of Vitamin C (t1/2) in Hours in Cohort B t(1/2)	6.46 hours Standard Deviation 1.44	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration.

Population: Overall number of participants analyzed includes any participants that were enrolled in the study and received at least one dose of Vitamin C.

The number of participants per cohort who experienced a Grade 3 or 4 adverse event (as defined by CTCAE v4.03) that was deemed possibly, probably, or definitely related to Vitamin C.

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=7 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 n=19 Participants Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 n=3 Participants Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 n=3 Participants Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 n=4 Participants Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 n=3 Participants A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 n=3 Participants A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 n=7 Participants A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 n=3 Participants A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 n=6 Participants A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Alkaline Phosphatase Increase	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Aspartate Aminotransferase Increase	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Alanine Aminotransferase Increase	0 Participants	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Anemia	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Hypokalemia	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Blood Bilirubin Increased	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Hypertension	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Fatigue	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Generalized Muscle Weakness	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Confusion	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Scrotal Pain	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Syncope	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Safety of High Dose Vitamin C Administration Using CTCAE 4.03. Hemolysis	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to 24 hours post-infusion

Population: Pharmacokinetics were not assessed for Cohort A and C. PK samples for 5 participants from Cohort B were not obtained and therefore only 16/21 participants were evaluable.

The serum concentration of vitamin C was serially measured following vitamin C infusion at 1.25 g/kg at various timepoints up to 24 hours post infusion to determine the maximum concentration (Cmax) in mM.

Outcome measures

Outcome measures
Measure	Cohort A: Vitamin C + Surgery n=16 Participants Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Maximum Concentration of Vitamin C in Hours in Cohort B	41.19 mM Standard Deviation 10.89	—	—	—	—	—	—	—	—	—

Other events: 5 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	Cohort A: Vitamin C + Surgery n=7 participants at risk Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort B Vitamin C Only n=19 participants at risk Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for up to 6 months. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 n=3 participants at risk Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 n=3 participants at risk Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 n=4 participants at risk Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 n=3 participants at risk Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 n=3 participants at risk A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 n=7 participants at risk A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 n=3 participants at risk A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 n=6 participants at risk A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Blood and lymphatic system disorders Anemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Psychiatric disorders Confusion	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Abdominal Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Generalized Muscle Weakness	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Anorexia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Fever	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Injury, poisoning and procedural complications Wound Infection	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Vomiting	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Reproductive system and breast disorders Scrotal Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Cardiac disorders Atrial Fibrillation	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Abdominal Distension	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Blood and lymphatic system disorders Hemolysis	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Syncope	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.

Other adverse events

Other adverse events
Measure	Cohort A: Vitamin C + Surgery n=7 participants at risk Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort B Vitamin C Only n=19 participants at risk Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for up to 6 months. Vitamin C: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.	Cohort C: Vitamin C + Y-90 Dose Level 1 n=3 participants at risk Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 2 n=3 participants at risk Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.	Cohort C: Vitamin C + Y-90 Dose Level 3 n=4 participants at risk Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 4 n=3 participants at risk Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.	Cohort C: Vitamin C + Y-90 Dose Level 5 n=3 participants at risk A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 6 n=7 participants at risk A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 7 n=3 participants at risk A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.	Cohort C: Vitamin C + Y-90 Dose Level 8 n=6 participants at risk A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
Gastrointestinal disorders Abdominal pain	28.6% 2/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	36.8% 7/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	57.1% 4/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Fatigue	28.6% 2/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	31.6% 6/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	57.1% 4/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 2/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Alkaline phosphatase increased	28.6% 2/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	26.3% 5/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	71.4% 5/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Alanine aminotransferase increased	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	21.1% 4/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	100.0% 7/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Blood bilirubin increased	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	42.9% 3/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Constipation	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	15.8% 3/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 2/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Vomiting	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	21.1% 4/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	42.9% 3/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 2/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Hypokalemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	21.1% 4/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	50.0% 2/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	50.0% 3/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Aspartate aminotransferase increased	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	21.1% 4/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	100.0% 7/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Nausea	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	26.3% 5/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	28.6% 2/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Blood and lymphatic system disorders Anemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	57.1% 4/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 4/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Hypoalbuminemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 2/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Fever	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	15.8% 3/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	28.6% 2/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Flank Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Generalized Muscle Weakness	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	42.1% 8/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	28.6% 2/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Headache	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Edema Limbs	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 2/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Reproductive system and breast disorders Pelvic Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Neutrophil Count Decreased	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Gastrointestinal disorders Other, Bleeding Gums	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Seizure	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Vascular disorders Hypertension	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	15.8% 3/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Cold Intolerance	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Respiratory, thoracic and mediastinal disorders Other: COVID-19 Infection	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Peripheral Sensory Neuropathy	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	15.8% 3/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Flu Like Symptoms	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Other: Increased Lactate Dehydrogenase	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Respiratory, thoracic and mediastinal disorders Upper Respiratory Infection	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Anal Hemorrhage	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Other: Blood in Stool	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Other: Neuropathy, Type Unspecified	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Abdominal distension	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Activity Change	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Anorexia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	66.7% 2/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Psychiatric disorders Anxiety	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Other: Bleeding Gums	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Bloating	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Chest Pain, unspecified	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Chills	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Dehydration	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Hypomagnesemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Diaphoresis	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Diarrhea	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Dizziness	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Other: Dry Heaves	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Creatinine Increased	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Edema face	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Injury, poisoning and procedural complications Fall	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: "Feeling Shaky"	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Flatulence	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Skin and subcutaneous tissue disorders Other: Folliculitis	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Hypocalcemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Neck Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	10.5% 2/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Weight Loss	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Cardiac disorders Other: Chest tightness/discomfort	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Back Pain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	75.0% 3/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Cardiac disorders Other: Tachycardia, unspecified	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Gastrointestinal disorders Ascites	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Renal and urinary disorders Urinary Frequency	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Musculoskeletal and connective tissue disorders Other: Loss of Hand Movement	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Platelet Count Decreased	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Lymphocyte Count Decreased	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Psychiatric disorders Insomnia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	42.9% 3/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Skin and subcutaneous tissue disorders Periorbital edema	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	25.0% 1/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Syncope	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Skin and subcutaneous tissue disorders Other: Rash (Unspecified)	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	16.7% 1/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Weight gain	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Metabolism and nutrition disorders Hyperglycemia	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Nervous system disorders Somnolence	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Hepatobiliary disorders Portal Vein Thrombosis	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Vascular disorders Hypotension	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Night Sweats	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Increased Thirst	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Appetite Change	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	14.3% 1/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
General disorders Other: Jaundice	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Investigations Other: Ketosis	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	5.3% 1/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Respiratory, thoracic and mediastinal disorders Rhinorrhea	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/19 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/4 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	33.3% 1/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/7 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/3 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.	0.00% 0/6 • Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration. Some study participants were enrolled in the trial, but did not receive study treatment, so they are not included in the at risk population. All enrolled participants were assessed for death. Only participants treated were assessed for adverse events. Two participants that were enrolled in Cohort B Vitamin C Only were withdrawn prior to receiving study treatment. One participant that was enrolled in Vitamin C + Y-90: Dose Level 8 was withdrawn from the study before receiving study treatment. Therefore they were not included in the at risk population for adverse events, only mortality.

Additional Information

Dr. Manish Shah, Sponsor-Investigator

Weill Cornell Medicine

Phone: 646-962-6200

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place